Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report documents a rare instance of hair loss associated with isoniazid initiation in a 32-year-old male undergoing antitubercular treatment.

The ILDS Newsletter reported on efforts to support albinism patients in Tanzania and dermatological conferences.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This review discusses the potential health benefits of Indian gooseberries, including blood glucose management and cardiovascular health, and highlights the need for additional research; no new clinical results are reported.

This study identified three EDAR gene variants potentially linked to hypohidrotic ectodermal dysplasia in three Pakistani families, which could aid in genetic counseling for similar cases.

In a reported case, the use of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, resulted in hair changes and acneiform eruptions as cutaneous side effects.

This article discusses the XV Congress of the Italian Society of Hair Restoration held in Ortigia and reports no clinical findings.

This study reported that Ayurvedic treatment involving the internal administration of Vidangarishta, Krimikutararasa, and Shatavari Guda, alongside external papaya exudate application, led to significant, rapid, and lasting improvements in alopecia areata in a week-long trial.

This study found that in an ex vivo model simulating alopecia areata, the DHODH inhibitor farudodstat reduced T-cell proliferation and MHC protein expression in hair follicles, suggesting it may protect against immune privilege collapse without cytotoxic effects.

This study demonstrated that the IVL-DrugFluidic® platform is effective for mass-producing finasteride-loaded polymeric microspheres for long-acting injectables, maintaining stable drug release without an initial burst for a month.

A woman developed lupus after taking hydroxyurea for two years.

This case report suggests that shodhana and shamana treatments may facilitate hair regrowth in a patient with índralupta, with improvements observed within 15 days.

This case report of an infant with IPEX syndrome highlights the importance of early recognition and treatment, as the patient experienced severe symptoms and succumbed before stem cell transplantation.

This study found that 3D imaging may serve as a promising tool for objectively evaluating facial vitiligo repigmentation after treatment with upadacitinib.

This study observed that individuals with Down syndrome exhibit early immune dysregulation, including multi-organ autoimmunity and hypercytokinemia, and found that the JAK inhibitor tofacitinib showed a good safety profile and reduced skin pathology in a Phase II trial.

Children need early diagnosis and treatment for iron-deficiency anemia to prevent learning problems and promote health.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This system overview describes the UTokyo Repository's role in storing and providing online access to digital resources from the University of Tokyo, reporting no new empirical findings or research results.

This course overview discusses educational sessions on hair restoration surgery and FUE techniques and reports no new research findings.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.

In this study, a hydro-alcoholic extract of Urtica dioica demonstrated in vitro antioxidant activity, potentially linked to its ferulic acid content.

This study discovered that TTR is expressed in the human placenta as early as 6 weeks gestation, with increased levels in the first trimester potentially facilitating thyroid hormone delivery to the fetus.

This survey in Riyadh Province found that most participants identified malnutrition as the leading cause of iron deficiency anemia and reported symptoms like weakness and cold extremities.

Cinainu is effective and safe for treating children's alopecia areata.

This study investigated the safety and efficacy of IV iron maltoside 1000 in treating iron-deficiency anemia among children with IBD and found a significant increase in hemoglobin levels by 6 weeks, maintained for up to a year, with minimal side effects reported.

Ivarmacitinib effectively regrows hair in severe alopecia areata.